Search Results

You are looking at 1 - 10 of 929 items for :

  • "NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines" x
  • Refine by Access: All x
Clear All
Full access

Robert A. Swarm

remains less than 0.01 to 0.1 mg per person per year. Current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) “go much further” than the WHO Analgesic Ladder, he noted. The NCCN Guidelines mandate universal screening for pain in all

Full access

Presenter: Shaji K. Kumar

have to come up with new treatment approaches to maintain control over a long period of time.” Monoclonal Gammopathies of Clinical Significance The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma outline the

Full access

Presenter: David S. Craig

. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Adult Cancer Pain: principles of pharmacogenetics [PAIN-N]. Version 1.2022. © 2022 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this

Full access

Presenter: Maria Alma Rodriguez

viability and history of allergic reactions before vaccination ( Figure 1 ). 1 Figure 1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Survivorship: risk assessment and screening and interventions [SIMIN-2]. Version 1

Full access

Presenters: Meena S. Moran and A. Marilyn Leitch

There have been numerous important changes to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer on locoregional management of early-stage breast cancer. For radiation therapy (RT), the criteria for axillary

Full access

Presenter: Reid M. Ness

In an effort to prevent colorectal cancer (CRC), the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations for screening based on a variety of risk factors and patient profiles. In the past 2 years, the NCCN

Full access

Presenters: Jane Yanagawa and Gregory J. Riely

recommended only for advanced and metastatic NSCLCs in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC and not for early-stage NSCLC ( Figure 1 ). Molecular testing for EGFR mutations and immunohistochemistry for PD-L1 are

Full access

Presenter: William J. Gradishar

antibody–drug conjugates in the pipeline, Dr Gradishar described. Hormone Receptor–Positive Disease CDK4/6 Inhibitors “Looking at the landscape of estrogen receptor–positive breast cancer, in the NCCN Clinical Practice Guidelines in Oncology [NCCN

Full access

Presenter: Julio M. Pow-Sang

said ( Figure 1 ). Figure 1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer: initial risk stratification and staging workup for clinically localized disease [PROS-2]. Version 3.2022. ©2022 National

Full access

Presenters: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop

, the American Joint Committee on Cancer (AJCC), and Brigham and Woman’s Hospital have all developed guidelines for staging SCC. The current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Squamous Cell Skin Cancer, in particular